Biocryst Pharmaceuticals Inc financial data

Symbol
BCRX on Nasdaq
Location
4505 Emperor Boulevard, Suite 200, Durham, NC
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -24.3%
Quick Ratio 3.78 % -70.3%
Debt-to-equity -208 %
Return On Equity 2.02 % -92.3%
Return On Assets -1.87 % +92.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 211M shares +1.65%
Common Stock, Shares, Outstanding 211M shares +1.64%
Entity Public Float 1.26B USD -4.4%
Common Stock, Value, Issued 2.11M USD +1.64%
Weighted Average Number of Shares Outstanding, Basic 210M shares +1.58%
Weighted Average Number of Shares Outstanding, Diluted 220M shares +6.27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 175M USD -10.5%
Costs and Expenses 524M USD +15.5%
Operating Income (Loss) 76.1M USD +285%
Nonoperating Income (Expense) -82.7M USD +17.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.62M USD +94.7%
Income Tax Expense (Benefit) 2.16M USD -231%
Net Income (Loss) Attributable to Parent -8.78M USD +92.9%
Earnings Per Share, Basic 0 USD/shares +91.8%
Earnings Per Share, Diluted 0 USD/shares +91.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.1M USD -13.2%
Accounts Receivable, after Allowance for Credit Loss, Current 91.3M USD +26%
Inventory, Net 5.23M USD -30.8%
Assets, Current 356M USD -16.7%
Property, Plant and Equipment, Net 8.4M USD +13.1%
Operating Lease, Right-of-Use Asset 7.73M USD -7.34%
Other Assets, Noncurrent 4.39M USD -72%
Assets 446M USD -9.13%
Accounts Payable, Current 5.57M USD -58.7%
Employee-related Liabilities, Current 48.6M USD +33.2%
Accrued Liabilities, Current 119M USD +14%
Liabilities, Current 190M USD +23.9%
Operating Lease, Liability, Noncurrent 8.43M USD +4.46%
Liabilities 834M USD -13.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.14M USD -50.3%
Retained Earnings (Accumulated Deficit) -1.75B USD -0.5%
Stockholders' Equity Attributable to Parent -388M USD +17.2%
Liabilities and Equity 446M USD -9.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.5M USD +48.7%
Net Cash Provided by (Used in) Financing Activities 529K USD
Net Cash Provided by (Used in) Investing Activities 27.1M USD -5.78%
Common Stock, Shares Authorized 450M shares 0%
Common Stock, Shares, Issued 211M shares +1.64%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 558K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 106M USD -5.45%
Interest Paid, Excluding Capitalized Interest, Operating Activities 9.15M USD +83.5%
Deferred Tax Assets, Valuation Allowance 449M USD +2.66%
Deferred Tax Assets, Gross 453M USD +2.69%
Operating Lease, Liability 8.77M USD -3.74%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.93M USD +91.9%
Lessee, Operating Lease, Liability, to be Paid 14.8M USD -1.47%
Property, Plant and Equipment, Gross 20.1M USD +5.26%
Operating Lease, Liability, Current 348K USD -66.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.46M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.15M USD -39.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.03M USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.51M USD -5.52%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 14.7M USD +2.46%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.54M USD +8.62%
Operating Lease, Payments 385K USD -26.7%
Additional Paid in Capital 1.36B USD +7.13%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 331K USD +8.17%
Share-based Payment Arrangement, Expense 82.6M USD +36.4%
Interest Expense 101M USD -5.93%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%